Skip to main content

Table 4 Univariate comparison of characteristics of patients who were anticoagulated and those who were not anticoagulated

From: Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study

Characteristic Anticoagulated
(n= 36)
Not anticoagulated
(n= 81)
P
  Mean ± SD or n (%) Mean ± SD or n (%)  
Female 34 (94.4%) 71(87.6%) 0.26
Age at CTD diagnosis, years 48.5 ± 14.3 51.1 ± 14.7 0.46
Age at PAH diagnosis*, years 59.7 ± 13.1 62.5 ± 10.6 0.23
Anti-phospholipid antibodies 8 (22.1%) 19 (23.5%) 0.74
Contraindication to anticoagulation 0 (0%) 18 (22.2%) 0.002
WHO functional class    
Class I 0 (0%) 9 (11.1%)  
Class II 3 (8.3%) 11 (13.6%) 0.09
Class III 32 (88.9%) 56 (69.1%)  
Class IV 1 (2.8%) 5 (6.2%)  
Baseline 6MWD, m 286.3 ± 116.4 339.5 ± 128.4 0.06
Baseline mRAP, mmHg 7.1 ± 4.3 6.9 ± 4.1 0.85
Baseline mPAP, mmHg 42.0 ± 11.5 33.4 ± 12.0 0.001
Pericardial effusion 9 (25.0%) 5 (6.2%) 0.004
Pulmonary vasodilator therapy    
   Monotherapy 13 (36.1%) 57 (71.3%)  
   Sequential monotherapy 2 (5.6%) 10 (12.5%) < 0.0001
   Combination therapy 21 (58.3%) 13 (16.3%)  
  1. * date of PAH diagnosis is the date of right heart catheterisation
  2. 6MWD, six minute walk distance; CTD, connective tissue disease; ILD, interstitial lung disease; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; PAH, pulmonary arterial hypertension; SD, standard deviation; SSc, systemic sclerosis; WHO, World Health Organization